According to a new report by Transparence Market Research, the global glaucoma treatment market is being crowded with branded drugs in tandem with rising number of generics, thereby creating significant competition among leading players in the market. This is further setting limits to the introduction of novel therapies, and several products are closing in on losing exclusivity. Late-stage pipeline drugs for glaucoma, however, hold promise for its treatment, as they are deemed to impart novel mechanism of action, which in turn will create opportunities for the market growth.

Read Report Overview: https://www.transparencymarketresearch.com/glaucoma-treatment-market.html

The report profiled key players underpinning expansion of the global market for glaucoma treatment, which include Allergan, Novartis AG, Merck & Co., Inc., Bausch & Lomb Incorporated, Akorn, Inc., Teva Pharmaceuticals, Santen, Pfizer, Inotek Pharmaceuticals, and Aerie Pharmaceuticals. According to the report, the global market for glaucoma treatment is expected to ride on a modest CAGR throughout the forecast period, 2017 to 2026. Revenues from treatment of glaucoma across the globe are estimated to close in nearly US$ 3,400 Mn by 2026-end.

Prevalence of glaucoma has been rising in tandem with growing geriatric population around the world, as older population is relatively more prone to glaucoma. Mounting number of patients with diabetes along with those having hereditary traits of glaucoma further contribute to the disease prevalence significantly. Several healthcare institutions and governments are taking initiatives for spreading the awareness of treatment options for patients with glaucoma. According to WHO, glaucoma is deemed to be the second largest cause for vision loss globally. Glaucoma, a leading reason for the preventable blindness, is linked with the chronic progressive optic neuropathy that results into irreversible vision loss by damaging the optic nerve.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16451

No treatments exist in the market currently for direct prevention of glaucoma. Several commercially available therapies, however, concentrate on curtailing increased level of intraocular pressure, a well-known risk factor associated with the development & progression of glaucoma. Product development strategies in the recent past have been impressive with surgery options, with several effective additions such as photodynamic therapy and laser therapy. However, excellent efficiency and efficacy of currently available drugs, particularly carbonic anhydrase inhibitors and prostaglandin analogs, have set barriers to the development of new therapy options.

Revenues to Remain Largest from North America’s Glaucoma Treatment Market

Revenues from the glaucoma treatment market in North America are expected to remain the largest, followed by those from the market in Europe. These two regions are projected to hold roughly two-third revenue share of the global glaucoma treatment market during the forecast period. In addition, North America and Europe are also forecast to prevail as fast-expanding markets for glaucoma treatment. Revenues from the market in Asia-Pacific excluding Japan (APEJ) will also remain significant, accounting for over 20% share of the market through the forecast period.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16451

On the basis of product type, prostaglandin analogs (PGAs) will continue to spearhead the global market for glaucoma treatment, in terms of revenues as well as sales expansion. Revenues from sales of prostaglandin for glaucoma treatment worldwide will latch onto more than 30% share of the market by 2026-end. Although alpha agonist currently accounts for a significant share of the market, demand for the product will record a slight decline over the forecast period.

ACG to Remain Largest Indication Segment in the Market

Based on indication, revenues from treatment of angle closure glaucoma (ACG) are anticipated to remain significantly larger than those combined from all the other indications of glaucoma. ACG has also been slated to prevail as the fast-expanding indication segment in the global glaucoma treatment market.

Hospital pharmacies are expected to hold their position of being the largest sales channel for glaucoma treatment drugs through the forecast period. In addition, revenues from sales of glaucoma treatment drugs in hospital pharmacies and online sales are expected to witness a parallel increase through 2026.

About us: 
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. 

Contact us: 
Transparency Market Research 
90 State Street, 
Suite 700, 
Albany 
NY - 12207 
United States 
Tel: +1-518-618-1030 
USA - Canada Toll Free 866-552-3453 
Email: sales@transparencymarketresearch.com 
Website: http://www.transparencymarketresearch.com/